<DOC>
	<DOCNO>NCT02389946</DOCNO>
	<brief_summary>The objective study assess safety efficacy Orsiro Sirolimus Eluting Coronary Stent System treatment subject three native de novo restenotic ( standard PTCA ) coronary artery lesion compare Xience coronary stent system .</brief_summary>
	<brief_title>Safety Effectiveness Orsiro Sirolimus Eluting Coronary Stent System Subjects With Coronary Artery Lesions</brief_title>
	<detailed_description>The BIOTRONIK BIOFLOW-V clinical trial prospective , multicenter , randomize , control trial combining data randomize subject data two historical study employ Bayesian approach . Subjects CAD qualify PCI stenting screen per protocol inclusion exclusion criterion achieve total 1,400 randomized subject . Eligible subject randomize 2:1 ratio , stratify study center , undergo percutaneous coronary revascularization either Orsiro Sirolimus Eluting Stent System ( treatment group ) Xience Everolimus Eluting Stent System ( control group ) . Subjects may receive treatment three target lesion , one two target lesion per target vessel , maximum two target vessel . The target lesion ( ) must de novo restenotic lesion ( ) ≤ 36 mm length native coronary artery ( y ) , reference vessel diameter 2.25-4.0 mm . Treatment restenotic lesion allow provide target lesion previously treat PTCA . All treatment study stent perform single index procedure . Note : Concurrent treatment non-target lesion index procedure allow . Randomized subject clinical follow-up 1 month , 6 month , 12 month 2 , 3 , 4 5 year follow index procedure . To assess non-inferiority Orsiro stent compare Xience stent , BIOFLOW-V randomize subject combine historical subject BIOFLOW-II BIOFLOW-IV randomized trial employ Bayesian approach . Only subject meet clinical angiographic eligibility criterion BIOFLOW-V trial include analysis .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Subject ≥18 year minimum age require legal adult consent country enrollment . 2 . Subject acceptable candidate PCI . 3 . Subject acceptable candidate CABG . 4 . Subject clinical evidence ischemic heart disease , stable unstable angina pectoris document silent ischemia . 5 . Subject eligible dual antiplatelet therapy treatment aspirin plus either , clopidogrel , prasugrel , ticagrelor ticlopidine . 6 . Subject provide write informed consent . 7 . Subject willing comply study followup requirement . Each target lesion/vessel must meet follow angiographic criterion subject eligible trial : 1 . Subject three target lesion two separate target vessel ( two target lesion one vessel one target lesion separate vessel ) . 2 . Target lesion must de novo restenotic lesion native coronary artery ; restenotic lesion must treat standard PTCA . 3 . Target lesion must major coronary artery branch ( target vessel ) . 4 . Target lesion must angiographic evidence ≥ 50 % &lt; 100 % stenosis ( operator visual estimate ) . If target lesion &lt; 70 % stenosed , clinical evidence ischemia positive functional study , CT , electrocardiography , FFR , post infarct angina . 5 . TIMI flow &gt; 1 . 6 . Target lesion must ≤ 36 mm length operator visual estimate . 7 . Target vessel RVD 2.254.0 mm operator visual estimate . 8 . Target lesion must treatable maximum two overlap stent . 1 . Subject clinical symptom and/or electrocardiogram ( ECG ) change consistent acute ST elevation myocardial infarction ( STEMI ) within 72 hour prior index procedure . Hemodynamically stable nonSTEMI ( NSTEMI ) subject eligible study enrollment . 2 . Subject hemodynamically unstable . 3 . Subject pregnant and/or breastfeed intend become pregnant duration study . 4 . Subject know allergy contrast medium adequately premedicated , know allergy thienopyridine , aspirin , heparin bivalirudin , L605 cobaltchromium ( CoCr ) alloy one major element ( cobalt , chromium , tungsten nickel ) , acrylic , fluoropolymers , silicon carbide , PLLA , sirolimus everolimus . 5 . Revascularization target vessel within 9 month prior index procedure previous PCI nontarget vessel within 30 day prior index procedure . 6 . Planned treatment lesion meeting angiographic inclusion exclusion criterion index procedure index procedure . 7 . Planned surgery within 6 month index procedure unless dual antiplatelet therapy maintain throughout perisurgical period . 8 . History stroke transient ischemic attack ( TIA ) within 6 month prior index procedure . 9 . Subjects active bleeding disorder , active coagulopathy , reason , ineligible DAPT . 10 . Subject refuse blood transfusion . 11 . Subject document left ventricular ejection fraction ( LVEF ) &lt; 30 % within 90 day prior index procedure . 12 . Subject dialysisdependent . 13 . Subject impaired renal function ( i.e. , blood creatinine &gt; 2.5 mg/dL 221 μmol/L determine within 7 day prior index procedure ) . 14 . Subject leukopenia ( i.e . &lt; 3,000 white blood cells/mm3 ) , thrombocytopenia ( i.e . &lt; 100,000 platelets/mm3 ) thrombocytosis ( i.e . &gt; 700,000 platelet/mm3 ) . 15 . Subject receive oral intravenous immunosuppressive therapy ( inhaled steroid permit ) , know lifelimiting immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus ; diabetes mellitus permit ) . 16 . Subject receive chronic anticoagulation ( e.g . coumadin , dabigatran , apixaban , rivaroxaban agent ) . 17 . Subject life expectancy &lt; 1 year . 18 . Subject participate another investigational ( medical device drug ) clinical study . Subjects may concurrently enrol postmarket study , long postmarket study device , drug protocol interfere investigational treatment protocol study . 19 . In investigator 's opinion , subject able comply followup requirement . Subjects exclude trial target lesions/vessels meet follow angiographic criterion : 1 . Target lesion locate within saphenous vein graft arterial graft . 2 . Target lesion restenotic lesion previously treat bare metal drug elute stent ( instent restenosis ) . 3 . Target lesion follow characteristic : 1 . Lesion location within leave main coronary artery , within 3 mm origin leave anterior descending ( LAD ) leave circumflex ( LCX ) . 2 . Involves side branch &gt; 2.0 mm diameter . Note : Lesions within 3 mm origin right coronary artery may treat . 4 . Target vessel/lesion excessively tortuous/angulated severely calcify , would prevent complete inflation angioplasty balloon . This assessment base visual estimation . 5 . Target vessel angiographic evidence thrombus . 6 . Target lesion totally occlude ( 100 % stenosis ) . 7 . Target vessel treat brachytherapy time prior index procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug elute coronary stent</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Bioabsorbable polymer</keyword>
	<keyword>DES</keyword>
</DOC>